MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection
-
By
-
Franziska Rodner
-
Klaus Schughart
-
Stephan Ludwig
-
André Schreiber
-
May 29, 2026
-
Clinical Scorecard: ATR-002, a MEK1/2 Inhibitor, Alters Host Transcriptomic Landscape and Influences Immune Regulatory Gene Expression During SARS-CoV-2 Infection
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Hospitalized COVID-19 patients with severe or critical illness. |
| Care Setting | |
Key Highlights
- NLRP1 identified as a target of MEK1/2 inhibition linked to hyperinflammation; clarify its role.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor for cytokine storm and inflammatory response in severe COVID-19 patients, including specific biomarkers.
Risks
Patient & Prescribing Data
Patients with severe or critical COVID-19.
Host-targeted antivirals like ATR-002 may provide dual benefits of antiviral and anti-inflammatory effects.
Clinical Best Practices
- Avoid combinational therapy of corticosteroids and DAAs due to potential drug interactions and impact on viral clearance.
Related Resources & Content
